Satralizumab Suppliers & Bulk Manufacturers
Available Forms: injection (prefilled syringe)
Available Strengths: 120mg
Reference Brands: ENSPRYNG (USA/EU)
Category: Neurology
Satralizumab is a humanized monoclonal antibody that targets the interleukin-6 (IL-6) pathway to reduce inflammatory activity in neuromyelitis optica spectrum disorder (NMOSD). It is indicated (as monotherapy or with immunosuppressants) for AQP4-antibody positive adults with NMOSD and is given by subcutaneous injection (loading doses at Weeks 0, 2, 4, then every 4 weeks maintenance). The approved commercial name in the US, EU and UK is ENSPRYNG and the licensed presentation is a single-use 120 mg/1 mL prefilled syringe. Common important safety notes include an increased risk of serious infections; screening for infections (including hepatitis B / TB) and vaccination status should be reviewed before starting therapy. Satralizumab is available in injection (prefilled syringe) and strengths such as 120mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Satralizumab is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Satralizumab can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Satralizumab is used to treat neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune condition that affects the optic nerves and spinal cord. It helps reduce inflammation and prevent relapses by blocking the interleukin-6 (IL-6) receptor, which plays a key role in the immune system’s inflammatory response.
Satralizumab is made from Satralizumab-mwge, a humanized monoclonal antibody that specifically targets the IL-6 receptor to control immune system overactivity.
The trade name of Satralizumab is Enspryng.
Satralizumab (Enspryng) is developed and manufactured by Chugai Pharmaceutical Co., Ltd., a member of the Roche Group, and marketed by Genentech in various countries.
The generic name of Satralizumab is Satralizumab-mwge.
The brand name of Satralizumab is Enspryng.
Satralizumab is manufactured in Japan and Switzerland by Chugai Pharmaceutical and Roche, and distributed globally under regulatory approvals for NMOSD treatment.
Related Products
Memantine
Strength:
5 mg, 10 mg, 10 mg/5 ml
Form: Tablets / Oral solution
Reference Brands: Namenda (USA), Ebixa (EU/UK)
View Details
Sodium Oxybate
Strength:
500 mg/ml
Form: Oral Solution
Reference Brands: Xyrem (USA/EU), Lumryz (USA/EU)
View Details
Quick Response Guaranteed | Verified Suppliers
